fda warning letter semaglutide october 2025 letters compounding Warns Novo Nordisk on Unreported Deaths February 17, 2026: Pennsylvania compounding – Compounded GLP-1s: Why doctors worry

Semaglutide is an injectable GLP-1 (glucagon-like peptide-1) receptor agonist developed by Novo Nordisk

doi: 10.3389/fnut.2025.1746176 Received 14 November 2025 Revised 03 December 2025 Accepted 17 December 2025 Published 12 January 2026 Volume 12 - 2025 Edited by Iris Joye, University of Guelph, Canada Reviewed by Soubhagya Tripathy, Indian Institute of Technology Kharagpur, India Prakasha R., Anand Agricultural University, India Updates Copyright 2026 Hao, Tan, Liu and Xin

Direct human oral dose-finding trials are limited

Studies examine the peptide's ability to maintain endothelium integrity and modulate vascular tone